Howard A Burris

Howard A Burris

UNVERIFIED PROFILE

Are you Howard A Burris?   Register this Author

Register author
Howard A Burris

Howard A Burris

Publications by authors named "Howard A Burris"

Are you Howard A Burris?   Register this Author

100Publications

9434Reads

25Profile Views

Patient Navigation in Cancer: The Business Case to Support Clinical Needs.

J Oncol Pract 2019 Nov 11;15(11):585-590. Epub 2019 Sep 11.

University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00230DOI Listing
November 2019

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lancet Gastroenterol Hepatol 2019 Sep 9;4(9):711-720. Epub 2019 Jul 9.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2468-1253(19)30189-XDOI Listing
September 2019

WITHDRAWN: Cardio-Oncology: Stronger Together.

J Am Coll Cardiol 2019 Jul 31. Epub 2019 Jul 31.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.07.041DOI Listing
July 2019

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

J Clin Oncol 2018 05 5;36(13):1291-1299. Epub 2018 Feb 5.

Dejan Juric, Massachusetts General Hospital Cancer Center, Boston; Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; Jordi Rodon and Josep Tabernero, Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona; Marta Gil-Martin, Catalan Institute of Oncology - Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain; Filip Janku, The University of Texas MD Anderson Cancer Center, Houston, TX; Howard A. Burris, Sarah Cannon Research Institute and Tennessee Oncology; Jordan Berlin, Vanderbilt-Ingram Cancer Center, Nashville, TN; Jan H.M. Schellens, Netherlands Cancer Institute, Amsterdam, the Netherlands; Mark R. Middleton, National Institute for Health Research, Oxford Biomedical Research Centre, Churchill Hospital, Oxford, United Kingdom; Martin Schuler, West German Cancer Center, University Duisburg-Essen, and German Cancer Consortium, Partner Site University Hospital Essen, Essen; Ruth Seggewiss-Bernhardt, Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg, Germany; Hope S. Rugo, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Douglas Bootle, David Demanse, Lars Blumenstein, and Cornelia Quadt, Novartis Pharma AG, Basel, Switzerland; Christina Coughlin, Novartis Pharmaceuticals Corporation, East Hanover, NJ; and José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.7107
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.7107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920739PMC
May 2018

Assessing the Value of Next-Generation Sequencing Tests in a Dynamic Environment.

Am Soc Clin Oncol Educ Book 2018 May;38:139-146

From Sarah Cannon, Nashville, TN; Memorial Sloan Kettering Cancer Center, New York, NY; Hartford HealthCare Cancer Institute, Hartford, CT, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_200825DOI Listing
May 2018

Phase II trial of preoperative pemetrexed plus carboplatin in patients with stage IB-III nonsquamous non-small cell lung cancer (NSCLC).

Lung Cancer 2018 04 31;118:6-12. Epub 2018 Jan 31.

Sarah Cannon Research Institute, Nashville, TN, United States; Tennessee Oncology, PLLC, Nashville, TN, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.009DOI Listing
April 2018

Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

Authors:
Howard A Burris

Expert Rev Anticancer Ther 2018 03 19;18(3):201-213. Epub 2018 Feb 19.

a Sarah Cannon Research Institute , Nashville , TN , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2018.1435275DOI Listing
March 2018

Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.

Lung Cancer 2018 03 12;117:38-43. Epub 2018 Jan 12.

Sarah Cannon Research Institute, Nashville, TN, 37203, USA; Tennessee Oncology, PLLC, Nashville, TN, 37203, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.007DOI Listing
March 2018

First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC).

Cancer Invest 2017 Sep 1;35(8):541-546. Epub 2017 Aug 1.

a Sarah Cannon Research Institute/Tennessee Oncology, PLLC , Nashville , Tennessee , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357907.2017.1344698DOI Listing
September 2017

TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.

Cancer Chemother Pharmacol 2017 Aug 10;80(2):261-273. Epub 2017 Jun 10.

Sarah Cannon Research Institute, 250 25th Avenue North, #100, Nashville, TN, 37203, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-017-3343-4
Publisher Site
http://dx.doi.org/10.1007/s00280-017-3343-4DOI Listing
August 2017

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.

J Clin Oncol 2017 Jun 2;35(18):2028-2036. Epub 2017 May 2.

Howard A. Burris and Jeffrey R. Infante, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN; Stephen M. Ansell, Mayo Clinic, Rochester, MN; John J. Nemunaitis, Mary Crowley Cancer Research Center, Dallas, TX; Geoffrey R. Weiss and Timothy Bullock, University of Virginia, Charlottesville, VA; Victor M. Villalobos and Branimir I. Sikic, Stanford Cancer Institute, Stanford, CA; Matthew H. Taylor, Oregon Health & Science University, Portland, OR; Donald W. Northfelt, Mayo Clinic, Scottsdale, AZ; William E. Carson III, The Ohio State University, Columbus, OH; Thomas R. Hawthorne, Thomas A. Davis, Michael J. Yellin, and Tibor Keler, Celldex Therapeutics, Hampton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.1508
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.1508DOI Listing
June 2017

Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment.

J Clin Oncol 2017 01 28;35(2):139-140. Epub 2016 Nov 28.

Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Laura A. Levit, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, The Children's Hospital of Philadelphia, Philadelphia, PA; Suanna S. Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Adam P. Dicker, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA; Mithat Gönen, Memorial Sloan Kettering Cancer Center, New York, NY; Stephen M. Keefe, University of Pennsylvania, Philadelphia, PA; Michael A. Postow, Memorial Sloan Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC; and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.4692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559890PMC
January 2017

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

N Engl J Med 2016 11 7;375(18):1738-1748. Epub 2016 Oct 7.

From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology-Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) - all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) - both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt-Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) - all in Nashville; National Cancer Center Singapore, Singapore (Y.-S.Y.); Netherlands Cancer Institute and BOOG Study Center, Amsterdam (G.S.S.); Institut de Cancérologie de l'Ouest/René Gauducheau, Saint-Herblain (M.C.), Institut Gustave Roussy, Université Paris Sud, Villejuif (F.A.), University Hospital of Besançon, Besançon (C.V.), and Centre Léon Bérard, Lyon (T.B.) - all in France; Duke University Medical Center, Durham, NC (K.L.B.); Dana-Farber Cancer Institute, Boston (E.P.W.); University of Ulm, Ulm (W.J.), Onkologische Praxis, Velbert (A.N.), University of Tübingen, Tübingen (E.-M.G.), and Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg (N.M.) - all in Germany; Tom Baker Cancer Centre, Calgary, AB, Canada (S.V.); University of Padua and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.); Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh (D.A.C.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); Florida Cancer Specialists-Sarah Cannon Research Institute, Fort Myers (L.L.H.); Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia (A.C.); Department of Oncology, Vejle Hospital, Vejle, Denmark (E.J.); Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russia (O.B.); Hospital Universitario Virgen de la Victoria, Institute of Biomedical Research in Málaga, Málaga, Spain (E.A.); Oslo University Hospital, Oslo (E.W.); Virginia Cancer Specialists, Arlington (A.M.F.); Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan (L.-M.T.); Rainier Hematology-Oncology, Northwest Medical Specialties, Puyallup, WA (S.B.); Novartis Pharmaceuticals, East Hanover, NJ (F.X., M.M., C.G., S.H.); and Novartis Pharma, Basel, Switzerland (F.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609709DOI Listing
November 2016

A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.

J Neurooncol 2016 09 16;129(2):281-8. Epub 2016 Jun 16.

Sarah Cannon Research Institute, 250 25th Avenue North, Suite 200, Nashville, TN, 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-016-2172-3DOI Listing
September 2016

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

Int J Nanomedicine 2015 10;10:1201-9. Epub 2015 Feb 10.

UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA ; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA ; UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, USA ; Carolina Center for Cancer Nanotechology Excellence, University of North Carolina, Chapel Hill, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJN.S62911DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334335PMC
May 2016

A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.

Cancer Chemother Pharmacol 2016 05 9;77(5):1079-86. Epub 2016 Apr 9.

Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-016-2986-xDOI Listing
May 2016

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

J Clin Oncol 2016 Mar 25;34(8):871-8. Epub 2016 Jan 25.

Georgina V. Long, Melanoma Institute Australia; The University of Sydney; Richard F. Kefford, Melanoma Institute Australia; The University of Sydney; Macquarie University, Sydney; Westmead Hospital, Westmead; Jonathan Cebon, Austin Health, Melbourne, Victoria, Australia; Jeffrey S. Weber and Ragini Kudchadkar, Moffitt Cancer Center, Tampa, FL; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute/Tennessee Oncology; Kevin B. Kim, California Pacific Medical Center; Adil Daud, Alain Algazi, University of California, San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, CA; Rene Gonzalez, Karl Lewis, University of Colorado; Gerald S. Falchook, Sarah Cannon Research Institute at HealthONE, Denver, CO; Jeffrey A. Sosman, Igor Puzanov, Vanderbilt University Medical Center, Nashville, TN; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Elizabeth Cunningham, Merck; Peng Sun, Amy S. Kline, Heather Del Buono, Diane Opatt McDowell, GlaxoSmithKline, Philadelphia, PA; Donald Lawrence and Kiran Patel, Incyte Corporation, Wilmington, DE; and Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.62.9345
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.9345DOI Listing
March 2016

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

J Clin Oncol 2016 Feb 26;34(5):419-26. Epub 2015 Oct 26.

Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; David Chen, Tetiana Taran, and David Lebwohl, Novartis Pharmaceuticals, East Hanover, NJ; Martine Piccart and Fabienne Lebrun, Université Libre de Bruxelles, Brussels; Ines Deleu, Oncology Centre, AZ Nikolaas, Sint-Nikolaas, Belgium; Hope S. Rugo, University of California, San Francisco; Ian Anderson, Redwood Regional Oncology Center, Santa Rosa, CA; Howard A. Burris III, Sarah Cannon Research Institute, Nashville, TN; Kathleen I. Pritchard, Sunnybrook Odette Cancer Centre and the University of Toronto, Toronto, Ontario, Canada; Mario Campone, Centre de Recherche en Cancerologie, Nantes-Saint-Herblain; Thomas Bachelot, Centre Léon Bérard, Lyon, France; Shinzaburo Noguchi, Osaka University Medical School; Norikazu Masuda, Osaka National Hospital, Osaka, Japan; Alejandra T. Perez, Memorial Cancer Institute, Hollywood, FL; Mikhail Shtivelband, Ironwood Cancer & Research Centers, Chandler, AZ; Shaker Dakhil, Cancer Center of Kansas, Wichita, KS; Douglas M. Robinson, Wei He, Abhishek Garg, E. Robert McDonald III, Hans Bitter, and Alan Huang, Novartis Institutes for BioMedical Research, Cambridge, MA; and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.1971DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070556PMC
February 2016

Developments in the use of antibody-drug conjugates.

Authors:
Howard A Burris

Am Soc Clin Oncol Educ Book 2013

From the Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EdBook_AM.2013.33.e99DOI Listing
December 2015

Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer.

Cancer Chemother Pharmacol 2015 May 15;75(5):993-1004. Epub 2015 Mar 15.

Department of Medical Oncology, Austin Health, Heidelberg, VIC, 3084, Australia,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2694-yDOI Listing
May 2015

American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.

J Clin Oncol 2015 Jan 15;33(3):278-84. Epub 2014 Dec 15.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; Laura A. Levit and Suanna Bruinooge, American Society of Clinical Oncology, Alexandria, VA; Peter C. Adamson, Children's Hospital of Philadelphia; Adam P. Dicker, Jefferson Medical College, Thomas Jefferson University; Stephen M. Keefe and Lynn M. Schuchter, University of Pennsylvania, Philadelphia, PA; Howard A. Burris IIII, Sarah Cannon Research Institute, Nashville, TN; Michael A. Carducci, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD; Mithat Gönen and Michael A. Postow, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael A. Thompson, Aurora Health Care, Milwaukee, WI; David M. Waterhouse, Oncology Hematology Care, Cincinnati, OH; and Susan L. Weiner, Children's Cause for Cancer Advocacy, Washington, DC.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/3/278.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.2635
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.2635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516884PMC
January 2015

Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.

Breast Cancer Res Treat 2014 Dec 6;148(3):535-40. Epub 2014 Nov 6.

Sarah Cannon Research Institute, 250 25th Avenue North, Suite 100, Nashville, TN, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-014-3189-y
Publisher Site
http://dx.doi.org/10.1007/s10549-014-3189-yDOI Listing
December 2014

Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.

J Clin Oncol 2014 Nov 6;32(33):3697-704. Epub 2014 Oct 6.

Douglas B. Johnson and Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center; Jeffrey R. Infante and Howard A. Burris III, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; Keith T. Flaherty and Donald P. Lawrence, Massachusetts General Hospital Cancer Center, Boston MA; Jeffrey S. Weber and Geoffrey T. Gibney, Moffitt Cancer Center, Tampa, FL; Kevin B. Kim and Gerald S. Falchook, University of Texas MD Anderson Cancer Center, Houston, TX; Richard F. Kefford and Georgina V. Long, Melanoma Institute Australia, University of Sydney and Westmead Hospital, Sydney, New South Wales; Jonathan Cebon, Joint Ludwig-Austin Oncology Unit, Austin Health, Melbourne, Victoria, Australia; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles; Alain Algazi and Adil Daud, University of California, San Francisco, San Francisco, CA; Lynn Schuchter, University of Pennsylvania Abramson Cancer Center; Nageatte Ibrahim, Peng Sun, Shonda Little, and Elizabeth Cunningham, GlaxoSmithKline, Philadelphia, PA; William H. Sharfman, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Robert R. McWilliams, Mayo Clinic, Rochester, MN; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Karl Lewis and Rene Gonzalez, University of Colorado, Denver, CO; and Kiran Patel, Incyte, Wilmington, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.3535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226803PMC
November 2014

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.

Nature 2014 Nov;515(7528):558-62

University of Nevada School of Medicine and US Oncology/Comprehensive Cancer Centers of Nevada, 3730 S. Eastern Avenue, Las Vegas, Nevada 89169, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature13904DOI Listing
November 2014

Successful treatment with dabrafenib (GSK2118436) in a patient with ganglioglioma.

J Clin Oncol 2014 Oct 10;32(29):e98-e100. Epub 2014 Feb 10.

Sarah Cannon Research Institute; and Tennessee Oncology, Nashville, TN.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.48.6852
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.6852DOI Listing
October 2014

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors.

Cancer Chemother Pharmacol 2014 Jul 13;74(1):125-30. Epub 2014 May 13.

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 3322 West End Avenue, Suite 900, Nashville, TN, 37203, USA,

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-014-2480-2
Publisher Site
http://dx.doi.org/10.1007/s00280-014-2480-2DOI Listing
July 2014

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

J Clin Oncol 2014 May 14;32(14):1437-44. Epub 2014 Apr 14.

Kathy D. Miller, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN; Reshma L. Mahtani, Sylvester Comprehensive Cancer Center, Miami, FL; Kathy S. Albain, Loyola University Chicago Stritch School of Medicine, Maywood, IL; Liang Fang, Glenn Michelson, Genentech, South San Francisco, CA; Howard A. Burris, Sarah Cannon Research Institute, Nashville, TN; Véronique Diéras, Institut Curie, Paris; Fabrice Andre, Institut Gustave Roussy, Villejuif, France; Nadia Harbeck, Interdisciplinary Breast Cancer, University of Cologne, Cologne; Nadia Harbeck, Breast Cancer University of Munich, Germany; Luca Gianni, San Raffaele Hospital, Milan; Diana Crivellari, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Italy; Sanne L. de Haas, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.52.6590DOI Listing
May 2014

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors.

Invest New Drugs 2014 Feb 16;32(1):135-44. Epub 2013 Apr 16.

Huntsman Cancer Institute, Division of Medical Oncology, University of Utah, 2000 Circle of Hope Drive, Suite 3380, Salt Lake City, UT, 84112, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-013-9952-9DOI Listing
February 2014

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Clin Cancer Res 2014 Jan 4;20(2):456-68. Epub 2013 Oct 4.

Authors' Affiliations: Research Oncology, Departments of Biostatistics, Product Development Oncology, and Translational Oncology, Genentech, Inc., South San Francisco, California; Indiana University Simon Cancer Center, Indianapolis, Indiana; Institute Gustave Roussy, Villejuif; Department of Medical Oncology, Institut Curie, Paris, France; Sarah Cannon Research Institute, Nashville, Tennessee; Loyola University Medical Center, Maywood, Illinois; University of Munich, Munich, Germany; and Division of Medical Oncology, Centro di Riferimento Oncologico, Instituto Nazionale Tumori Aviano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-0358DOI Listing
January 2014

Population pharmacokinetics of PEGylated liposomal CPT-11 (IHL-305) in patients with advanced solid tumors.

Eur J Clin Pharmacol 2013 Dec 30;69(12):2073-81. Epub 2013 Aug 30.

UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, 27599, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00228-013-1580-yDOI Listing
December 2013

A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.

Cancer Chemother Pharmacol 2013 Oct 25;72(4):861-8. Epub 2013 Aug 25.

South Texas Accelerated Research Therapeutics (START), 4383 Medical Dr, Room 4042, San Antonio, TX, 78229, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2267-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3784064PMC
October 2013

Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.

Invest New Drugs 2013 Aug 8;31(4):891-9. Epub 2012 Nov 8.

Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-012-9887-6DOI Listing
August 2013

PARP inhibitors: pitfalls and promises.

Lancet Oncol 2013 Aug 28;14(9):798-9. Epub 2013 Jun 28.

Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70276-6DOI Listing
August 2013

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.

Authors:
Howard A Burris

Cancer Chemother Pharmacol 2013 Apr 3;71(4):829-42. Epub 2013 Feb 3.

Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN 37203, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-012-2043-3
Publisher Site
http://dx.doi.org/10.1007/s00280-012-2043-3DOI Listing
April 2013

New treatment paradigms for optimizing survival in advanced and metastatic breast cancer.

Clin Adv Hematol Oncol 2012 Aug;10(8 Suppl 13):1-14; quiz 15-6

Mayo Clinic Cancer Center, Mayo Clinic, Jacksonville, Florida, USA.

View Article

Download full-text PDF

Source
August 2012